New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.

The following studies are currently available for enrollment.

RESEARCH LOCATION: ORLANDO

Clinical Trial for Wet Age-Related Macular Degeneration (AMD)

Protocol ID: RTE888-E001 (ALCON)
ClinicalTrials.gov ID: NCT05769153
Sponsor: Alcon Research

This clinical trial is testing a new treatment called AR-14034 Sustained Release (SR), a tiny implant that slowly releases medicine into the eye. It’s designed for people with wet AMD, a condition that can cause vision loss. The goal is to find out how safe and effective this treatment is—and whether it can reduce the need for frequent eye injections. The study has two parts: the first tests different doses in a small group, and the second compares the implant to a standard treatment (aflibercept) in a larger group.

Clinical Trial for Wet Age-Related Macular Degeneration (AMD)

Protocol ID: MR45638 (CONSTANCE)
ClinicalTrials.gov ID: NCT06795048
Sponsor: F. Hoffmann-La Roche Ltd.

This study is testing faricimab, a treatment for people with wet AMD. It aims to find out how safe and effective faricimab is when given as eye injections every few months. The trial compares two treatment approaches to see which works best and lasts longest. Participants must be new to treatment in the study eye.

Clinical Trial for Wet Age-Related Macular Degeneration (AMD)

Protocol ID: ADVM-022-12 (ARTEMIS)
ClinicalTrials.gov ID: NCT03748784
Sponsor: Adverum Biotechnologies

This trial is studying ADVM-022, a gene therapy designed to treat wet AMD with a single injection. The therapy helps the eye produce its own medicine to reduce abnormal blood vessel growth and preserve vision. The goal is to reduce the need for frequent injections and improve long-term outcomes.

Clinical Trial for Macular Neovascularization Secondary to AMD

Protocol ID: 4D-150-C003 (4Front-1)
ClinicalTrials.gov ID: NCT06864988
Sponsor: 4D Molecular Therapeutics

This Phase 3 trial is testing 4D-150, a gene therapy given as a single eye injection to treat macular neovascularization caused by AMD. It compares 4D-150 to aflibercept to see which treatment works better and lasts longer.

Clinical Trial for Diabetic Macular Edema (DME)

Protocol ID: EYE-RES-103 (BRUNELLO)
ClinicalTrials.gov ID: NCT06571045
Sponsor: EyeBio

This study is testing EYE103, a new treatment for diabetic macular edema. It compares two doses of EYE103 to ranibizumab to see which works best. In the first year, patients receive monthly injections, and in the second year, treatment is adjusted based on individual needs. The goal is to improve vision and reduce swelling in the retina.

Clinical Trial for Geographic Atrophy Secondary to AMD

Protocol ID: R3918-AMG2326 (SIENNA)
ClinicalTrials.gov ID: NCT06541704
Sponsor: Regeneron Pharmaceuticals

This trial is studying two experimental drugs—pozelimab and cemdisiran—to slow the progression of geographic atrophy, a late-stage form of AMD that affects central vision. The study compares these drugs to a placebo and looks at how well they work, how safe they are, and how the body responds to them.

---

RESEARCH LOCATION: JACKSONVILLE

Clinical Trial for Macular Neovascularization Secondary to AMD

Protocol ID: 4D-150-C003 (4Front-1)
ClinicalTrials.gov ID: NCT06864988
Sponsor: 4D Molecular Therapeutics

This Phase 3 trial is testing 4D-150, a gene therapy delivered via a single intravitreal injection. It’s designed to treat macular neovascularization caused by AMD by enabling the eye to produce its own anti-VEGF medicine. The study compares 4D-150 to aflibercept (EYLEA®) to evaluate safety, effectiveness, and durability. The trial is actively recruiting.

Clinical Trial for Wet Age-Related Macular Degeneration (AMD)

Protocol ID: ADVM-022-12 (ARTEMIS / LUNA)
ClinicalTrials.gov ID: NCT05536973
Sponsor: Adverum Biotechnologies

This Phase 2 trial is evaluating the safety and effectiveness of ADVM-022, a gene therapy designed to reduce the need for frequent anti-VEGF injections in patients with wet AMD. The therapy uses a viral vector to deliver aflibercept directly into the eye, aiming for long-term treatment with a single injection. Participants are randomized to receive one of two doses, each paired with different steroid regimens to manage inflammation. Only one eye per participant is treated, and the study will follow patients for up to five years.

Clinical Trial for Diabetic Retinopathy of Non-Proliferative Type (NPDR)

Protocol ID: 1436-0007 (CRIMSON)
ClinicalTrials.gov ID: NCT06321302
Sponsor: Boehringer Ingelheim Pharmaceuticals Inc

This clinical trial is investigating BI 764524, an investigational therapy for moderately severe to severe NPDR. The study evaluates three dosing regimens and includes both sham and aflibercept control groups. It aims to assess safety, tolerability, and efficacy over a 72-week period. The trial is actively recruiting.

Clinical Trial for Diabetic Retinopathy of Non-Proliferative Type (NPDR)

Protocol ID: VX01-DR-201
ClinicalTrials.gov ID: NCT06770933
Sponsor: Vantage Biosciences Ltd

This Phase 2 trial is evaluating VX-01, an oral therapy targeting neurovascular inflammation in NPDR. The study is double-masked and placebo-controlled, assessing safety and efficacy over 52 weeks of treatment followed by a 12-week observation period. The trial is actively recruiting.

Clinical Trial for Diabetic Macular Edema

Protocol ID: GR43828 (THAMES)
ClinicalTrials.gov ID: NCT06850922
Sponsor: Genentech, Inc.

This Phase I/II trial is evaluating RO7446603, administered alone or in combination with aflibercept or faricimab, for the treatment of diabetic macular edema. The study assesses safety, tolerability, pharmacokinetics, and efficacy across multiple dosing strategies. We are actively recruiting for this trial.

---

For more information about clinical trials or if you should have any questions, please feel free to contact us.